<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03703271</url>
  </required_header>
  <id_info>
    <org_study_id>ZJHGTN1212</org_study_id>
    <nct_id>NCT03703271</nct_id>
  </id_info>
  <brief_title>Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia</brief_title>
  <official_title>A Prospective Randomized Multicenter Clinical Control Study of Hysteroscopic Repeat Curettage as the Primal Management of Low-risk Postmolar Gestational Trophoblastic Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Women's Hospital School Of Medicine Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Women's Hospital School Of Medicine Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of hysteroscopic repeat curettage as the first-line treatment in low-risk postmolar&#xD;
      gestational trophoblastic neoplasia compared with the MTX single drug chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gestational trophoblastic neoplasia (GTN) is a group of malignant tumors derived from&#xD;
      placental trophoblastic cells, most of which are secondary to hydatidiform mole, and 95% of&#xD;
      GTN patients present low-risk gestational trophoblastic neoplasia(LR-GTN).In the 1960s and&#xD;
      1970s, with the in-depth study of the disease, it was found that the malignant tumor was&#xD;
      highly sensitive to chemotherapy and had ideal tumor marker HCG to guide the treatment and&#xD;
      follow-up. Therefore, GTN was the best malignant tumor with the overall cure rate of LR-GTN&#xD;
      nearly 100%.MTX single-drug multi-course chemotherapy is the classic treatment of LR-GTN&#xD;
      recommended by FIGO, but most patients can develop gastrointestinal, blood and liver toxicity&#xD;
      during chemotherapy. In addition, the longer treatment cycle also brings a lot of discomfort&#xD;
      to patients.&#xD;
&#xD;
      In recent years, some scholars proposed that the selection of treatment regimen of LR-GTN&#xD;
      secondary to hydatidiform pregnancy should consider the toxic and side effects of&#xD;
      chemotherapy, the maintenance of patients' physiological functions and quality of&#xD;
      life.Retrospective studies abroad have shown that LR-GTN delayed chemotherapy for&#xD;
      hydatidiform mole pregnancy only started chemotherapy for LR-GTN at a certain stage of&#xD;
      progression, and the results did not change the prognosis of LR-GTN but reduced the rate of&#xD;
      chemotherapy.In addition, for some patients with ultra-low risk of LR-GTN in hydatidiform&#xD;
      pregnancy undergoing hysteroscopic repeat curettage , the rate of chemotherapy can be&#xD;
      reduced, the related costs can be reduced and the quality of life of patients can be&#xD;
      improved.&#xD;
&#xD;
      In this prospective, multicenter, randomized, controlled clinical study, with the routine use&#xD;
      of a gleam of MTX single drug treatment scheme for comparison, comparing uterine cavity again&#xD;
      emptying delay chemotherapy guided by parallel hysteroscopy surgery clinical curative effect&#xD;
      and adverse reaction, which discuss after hydatidiform mole ultra-low dangerous GTN patients&#xD;
      with uterine cavity emptying again guided by hysteroscopy surgery as a line of ultra low&#xD;
      dangerous GTN patients after hydatidiform mole security and feasibility of the treatmen&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete remission rate in firstline treatment</measure>
    <time_frame>2 years</time_frame>
    <description>The investigators may calculate the rate of complete response at the preliminary end point of the trail</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications of hysteroscopic repeat curettage surgery</measure>
    <time_frame>2 years</time_frame>
    <description>The investigators may record the complications of hysteroscopic repeat curettage surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events as assessed by the WHO</measure>
    <time_frame>2 years</time_frame>
    <description>The investigators may record the adverse events of chemotherapy as assessed by the WHO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate (OR)</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival Rate of the two group patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian functional evaluation</measure>
    <time_frame>2 years</time_frame>
    <description>The investigators may test serum level of anti-mullerian hormone (AMH) every 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pregnancy rate</measure>
    <time_frame>2 years</time_frame>
    <description>To calculate the pregnancy rate in an actuarial manner using the Kaplan-Meier method at the end of the trail</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual cycle resuming rate</measure>
    <time_frame>2 years</time_frame>
    <description>The investigators record the time of menstrual cycle resuming after chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Gestational Trophoblastic Neoplasia</condition>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate 0.4mg/kg·d, im ,*5d started at the first day of cycle, two weeks a cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hysteroscopic repeat curettage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>single-agent 5-day methotrexate, two weeks a cycle</description>
    <arm_group_label>chemotherapy</arm_group_label>
    <other_name>Methotrexate chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hysteroscopic repeat curettage</intervention_name>
    <description>Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>complete curettage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  low-risk postmolar gestational trophoblastic neoplasia (GTN)&#xD;
&#xD;
          -  World Health Organization(WHO) risk score≤4&#xD;
&#xD;
          -  Age≤60 years; female, Chinese women&#xD;
&#xD;
          -  Initial treatment&#xD;
&#xD;
          -  Performance status: Karnofsky score≥60&#xD;
&#xD;
          -  Laboratory tests: WBC≥3.5×10(9)/L, ANC≥1.5×10(9)/L, PLT≥80×10(9)/L, serum bilirubin≤&#xD;
             1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of&#xD;
             normal,blood urea nitrogen, Cr≤ normal&#xD;
&#xD;
          -  Provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with unconfirmed diagnosis of GTN&#xD;
&#xD;
          -  Patients with placental-site trophoblastic tumor (PSTT) or epithelioid trophoblastic&#xD;
             tumor (ETT)&#xD;
&#xD;
          -  WHO risk score ≥5分&#xD;
&#xD;
          -  The diameter of a single metastatic lesion in the lung was ≥2cm&#xD;
&#xD;
          -  The number of lung CT metastases was≥ 5&#xD;
&#xD;
          -  With severe or uncontrolled internal disease, unable to receive chemotherapy&#xD;
&#xD;
          -  Concurrently participating in other clinical trials&#xD;
&#xD;
          -  Unable or unwilling to sign informed consents&#xD;
&#xD;
          -  Unable or unwilling to abide by protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Weiguo Lv</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiguo Lv, Doctor</last_name>
      <phone>13588193832</phone>
      <email>13588193832@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postmolar</keyword>
  <keyword>Gestational Trophoblastic Neoplasia</keyword>
  <keyword>hysteroscopic</keyword>
  <keyword>repeat curettage</keyword>
  <keyword>methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

